was recommended in most patients who had a primary nonresponse to the first TNFi, under the assumption that TNF was not the key inflammatory mediator in these patients. Continuing treatment with the first TNFi could be considered if additional time was believed important to assess the response fully, or if a higher dose or shorter dosing interval was thought to be beneficial. In patients who relapse after an initial response (i.e., secondary nonresponse), the panel judged that treatment with a